Case-Control Genome-Wide Association Study of Persistent Attention-Deficit Hyperactivity Disorder Identifies FBXO33 as a Novel Susceptibility Gene for the Disorder by Sanchez-Mora, C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/154715
 
 
 
Please be advised that this information was generated on 2019-12-04 and may be subject to
change.
Case–Control Genome-Wide Association Study of Persistent
Attention-Deficit Hyperactivity Disorder Identifies FBXO33 as
a Novel Susceptibility Gene for the Disorder
Cristina Sa´nchez-Mora1,2,3, Josep A Ramos-Quiroga2,3,4, Rosa Bosch2,3, Montse Corrales2,
Iris Garcia-Martı´nez1,2, Mariana Nogueira2, Mireia Pagerols1,2, Gloria Palomar2, Vanesa Richarte2,
Raquel Vidal2, Alejandro Arias-Vasquez5,6,7, Mariona Bustamante8,9,10,11, Joan Forns8,9,10,
Silke Gross-Lesch12, Monica Guxens8,9,10, Anke Hinney13, Martine Hoogman5, Christian Jacob12,
Kaya K Jacobsen14, Cornelis C Kan6, Lambertus Kiemeney15, Sarah Kittel-Schneider12, Marieke Klein5,
Marten Onnink5,6, Olga Rivero16, Tetyana Zayats14, Jan Buitelaar7,17, Stephen V Faraone18,
Barbara Franke5,6, Jan Haavik14, Stefan Johansson14, Klaus-Peter Lesch16, Andreas Reif12, Jordi Sunyer8,9,10,
Mo`nica Baye´s19, Miguel Casas2,3,4, Bru Cormand20,21,22,23 and Marta Ribase´s*,1,2,3,23
1Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addictions, Vall d’Hebron Research Institute (VHIR), Universitat Auto`noma de
Barcelona, Barcelona, Spain; 2Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 3Biomedical Network Research Centre on
Mental Health (CIBERSAM), Barcelona, Spain; 4Department of Psychiatry and Legal Medicine, Universitat Auto`noma de Barcelona, Barcelona, Spain;
5Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands;
6Department of Psychiatry, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands;
7Department of Cognitive Neuroscience, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The
Netherlands; 8Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; 9IMIM (Hospital del Mar Medical Research Institute),
Barcelona, Spain; 10CIBER Epidemiologı´a y Salud Pu´blica (CIBERESP), Madrid, Spain; 11Centre for Genomic Regulation (CRG), Barcelona, Spain;
12Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wu¨rzburg, Wu¨rzburg, Germany; 13Department of Child and
Adolescent Psychiatry, University Duisburg-Essen, Essen, Germany; 14Department of Biomedicine, University of Bergen, K.G. Jebsen Center for Research on
Neuropsychiatric Disorders, Bergen, Norway; 15Department for Health Evidence, Radboud University Medical Center, Radboud Institute for Health
Sciences, Nijmegen, The Netherlands; 16Division of Molecular Psychiatry, Department of Psychiatry, Psychosomatics and Psychotherapy, University
Hospital Wu¨rzburg, Wu¨rzburg, Germany; 17Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands; 18Departments of
Psychiatry and Neuroscience & Physiology, SUNY Upstate Medical University, Syracuse, NY, USA; 19Centro Nacional de Ana´lisis Geno´mico (CNAG), Parc
Cientı´fic de Barcelona (PCB), Barcelona, Spain; 20Department of Genetics, University of Barcelona, Catalonia, Spain; 21Biomedical Network Research
Centre on Rare Diseases (CIBERER), Madrid, Spain; 22Institute of Biomedicine of the University of Barcelona (IBUB), Catalonia, Spain
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with high heritability. At least 30% of patients diagnosed
in childhood continue to suffer from ADHD during adulthood and genetic risk factors may play an essential role in the persistence of the
disorder throughout lifespan. To date, genome-wide association studies (GWAS) of ADHD have been completed in seven independent
datasets, six of which were pediatric samples and one on persistent ADHD using a DNA-pooling strategy, but none of them reported
genome-wide significant associations. In an attempt to unravel novel genes for the persistence of ADHD into adulthood, we conducted the
first two-stage GWAS in adults with ADHD. The discovery sample included 607 ADHD cases and 584 controls. Top signals were
subsequently tested for replication in three independent follow-up samples of 2104 ADHD patients and 1901 controls. None of the findings
exceeded the genome-wide threshold for significance (PGCo5e 08), but we found evidence for the involvement of the FBXO33 (F-box
only protein 33) gene in combined ADHD in the discovery sample (P¼ 9.02e 07) and in the joint analysis of both stages (P¼ 9.7e 03).
Additional evidence for a FBXO33 role in ADHD was found through gene-wise and pathway enrichment analyses in our genomic study.
Risk alleles were associated with lower FBXO33 expression in lymphoblastoid cell lines and with reduced frontal gray matter volume in a
sample of 1300 adult subjects. Our findings point for the first time at the ubiquitination machinery as a new disease mechanism for adult
ADHD and establish a rationale for searching for additional risk variants in ubiquitination-related genes.
Neuropsychopharmacology (2015) 40, 915–926; doi:10.1038/npp.2014.267; published online 26 November 2014
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INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD; OMIM:
143465) is a neurodevelopmental disorder characterized by
inappropriate levels of hyperactivity, impulsivity, and/or
inattention that affects 5–6% of children and persists into
adulthood in 30–50% of ADHD patients diagnosed in
childhood (Faraone et al, 2000b; Kessler et al, 2005; Kooij
et al, 2005). Previous work supports a strong genetic load in
ADHD, which places it among the most heritable psychia-
tric disorders with an estimated heritability of 76%
(Biederman, 2005; Biederman and Faraone, 2005; Franke
et al, 2012).
The first investigations on genes underlying ADHD
focused on genome-wide linkage studies or hypothesis-driven
candidate gene association analyses. In most cases, however,
these failed to identify consistent and replicable genetic
factors and provide modest evidence for the involvement of
some specific genes on the basis of meta-analysis (Faraone
et al, 2005; Franke et al, 2012; Gizer et al, 2009). This
situation, along with advances in high-throughput technol-
ogies, stimulated a turn towards genome-wide association
studies (GWAS). To date, GWAS of ADHD have been
completed in seven independent datasets, six of which used
pediatric samples (Franke et al, 2009; Hinney et al, 2011;
Lesch et al, 2008; Mick et al, 2010; Neale et al, 2008; Neale
et al, 2010a; Stergiakouli et al, 2012; Yang et al, 2013). None
of them reported genome-wide significant associations and,
apart from the possible involvement of cadherin 13 (CDH13)
identified in three reports (Lesch et al, 2008; Neale et al, 2008;
Neale et al, 2010a), there is limited overlap between them or
with previous linkage or candidate gene association studies.
In addition, none of the ‘classic’ candidate genes for ADHD
were found among the top findings of any GWAS study.
Neale et al (2008), carried out the first GWAS on ADHD
in 909 affected triads and identified nominal associations
for XKR4 and FAM190A, two genes expressed in the
cerebellum. A second family-based multi-site GWAS
comprised of 735 affected-offspring trios highlighted the
SLC9A9 gene (Mick et al, 2010). Four additional case–
control GWAS were also conducted in childhood ADHD
and unscreened controls. Neale et al, genotyped 896 cases
and 2455 controls and found CDH13 and PRKG1 among the
top-ranked genes nominally associated with ADHD, while
the other three studies yielded no significant evidence
of association neither in the discovery cohort nor in the
replication attempts on different datasets (Hinney et al,
2011; Neale et al, 2010a; Stergiakouli et al, 2012; Yang et al,
2013). Finally, a single GWAS analysis has been reported on
persistent ADHD. It used a DNA-pooling strategy in a
sample of 343 adults with ADHD and 304 controls in
conjunction with linkage analysis and pointed to several
chromosomal regions likely to contain allelic variants
influencing susceptibility to ADHD (Lesch et al, 2008). So
far, following the first analysis by Neale et al, secondary
analyses considering the same dataset were conducted on
ADHD-related phenotypes, such as quantitative measures
of DSM-IV ADHD symptoms, age at onset of ADHD
symptoms, or conduct problems. None of them identified
single-nucleotide polymorphisms (SNPs) achieving genome-
wide significance, with the most significant markers located
in CDH13 and GFOD1 (Lasky-Su et al, 2008a; Lasky-Su et al,
2008b). All these negative results suggest that an even larger
sample may be required, in analogy to approaches in
schizophrenia and bipolar disorder where larger sample size
did result in significant findings (Ripke et al, 2013a;
Ruderfer et al, 2013). However, the first large-scale meta-
analysis of ADHD GWAS datasets in 2064 trios, 896 cases,
and 2455 controls from four previous studies also failed to
identify any genome-wide significant association with
childhood ADHD (Neale et al, 2010b).
In an attempt to unravel novel genes and biological
pathways related to ADHD, we aimed to improve the design
of previous GWAS in ADHD through reducing hetero-
geneity in the discovery cohort by (1) considering persistent
ADHD, which may be influenced by a stronger genetic load
than remitting ADHD (Biederman et al, 1996; Chang et al,
2013; Faraone et al, 2000a); (2) recruiting patients from a
restricted geographic area by a single clinical group and
following a single assessment protocol, which may facilitate
the identification of risk variants that might be neglected by
a broader recruitment approach used in previous multi-site
GWAS; (3) not only considering the overall ADHD sample,
but also the combined and inattentive clinical subtypes
that may be influenced by shared as well as specific genetic
factors; and (4) using screened, non-ADHD controls.
Following this strategy we conducted a two-stage case–
control GWAS in adulthood ADHD. The first phase
included a discovery cohort of 607 adults with ADHD and
584 controls from Spain. Top signals were subsequently
tested for replication in three independent follow-up
cohorts including 2104 adults with ADHD and 1901 controls
from three European countries (Germany, The Netherlands,
and Norway) integrated in The International Multicentre
persistent ADHD CollaboraTion (IMpACT).
MATERIALS AND METHODS
Participants
Clinical information of the studied cohorts is included in
Supplementary Table S1 and Supplementary Material. Briefly,
the discovery cohort consisted of 607 adulthood ADHD
cases (61% combined, 35% inattentive, 3.5% hyperactive-
impulsive and 0.5% with undefined subtype) and 584
healthy controls from Spain. All patients were adults of
Caucasian origin and met Diagnostic and Statistical Manual
for Mental Disorders-IV (DSM-IV) criteria for ADHD. The
diagnosis of ADHD was evaluated with the Structured
Clinical Interview for DSM-IV Axis I and II Disorders
(SCID-I and SCID-II) and the Conner’s Adult ADHD
Diagnostic Interview for DSM-IV (CAADID Parts I and
II). For the replication study, 2104 adult ADHD patients and
1901 controls of Caucasian origin from three European
countries (Germany, The Netherlands and Norway; for
more information see Sa´nchez-Mora et al, 2010) were
recruited at three sites of the IMpACT (Supplementary
Table S1). Consensus eligibility criteria for the current study
across all sites were a diagnosis of ADHD according to
the diagnostic criteria of DSM-IV, onset before the age of
7 years via retrospective diagnosis (which was confirmed by
a family member, wherever possible), lifelong persistence,
and current diagnosis. The study was approved by the ethics
committee of each institution and informed consent was
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obtained from all participants in accordance with the
Declaration of Helsinki.
Study Design, Genotyping, and Quality Control
Assessment
To identify loci conferring susceptibility to ADHD, we
carried out a two-stage case–control GWAS. In the initial
discovery phase we performed genome-wide genotyping
with the Illumina HumanOmni1-Quad BeadChip platform
in 607 adults with ADHD and 584 healthy controls. Quality
control was implemented at the individual and SNP level
using PLINK (Purcell et al, 2007) and included filtering
subjects with low call rate (o98%) or gender discrepancy
followed by filtering SNPs with minor allele frequency
(MAF)o0.01, Hardy–Weinberg equilibrium test P-values,
PHWEo1e 06 or call rateo0.99 in either cases or
controls. Top signals were further evaluated in three
independent follow-up cohorts from Germany, The Nether-
lands, and Norway consisting of 2104 cases and 1901
controls. The replication cohorts were genotyped using the
Kompetitive Allele Specific PCR (KASP) technology (LGC
Genomics, UK). Clinical information of the studied cohorts
is included in Supplementary Table S1 and Supplementary
Material.
Statistical Analysis
Genome-wide association study. Initially, 607 cases and
584 controls were genotyped for 1 138 747 markers. In total,
five samples were excluded from the analysis due to low call
rate. After stringent quality control assessment, a total of
794 090 SNPs with a mean call rate of 0.9994 for the
remaining 603 cases and 583 controls were included in the
study. Genome-wide association analysis was performed
using the Cochran–Armitage trend test with PLINK. The
genomic inflation factor (l) was calculated and used to
correct for the degree of inflations. Quantile–quantile and
Manhattan plots were drawn using the SnpStats (Clayton,
2013) and Gap R packages (Zhao, 2013). The genome-wide
significance threshold was calculated by considering the
three ADHD clinical subtypes and was set at Po1.7e 08
(5e 08/3). The phenotypic variance explained by all
autosomal SNPs for ADHD was calculated with GCTA
software (Yang et al, 2013). The gene-based association
analysis was performed with the VEGAS software following
the default settings and considering the HaMap CEU
samples to estimate the linkage disequilibrium (LD)
structure (Liu et al, 2010). The ALIGATOR software was
used to test for over-representation of biological pathways,
as indexed by gene ontology (GO) terms, considering genes
(RefSeq transcript plus 20 kb up and downstream) with
at least one SNP showing Po0.05, 10 000 replicate gene
lists and 10 000 replicate studies (Holmans et al, 2009).
ALIGATOR corrects for variable gene size, for the presence
of LD between SNPs and for overlapping genes through a
random selection of SNPs for generation of replication gene
lists that are used to calculate the category-specific P-value.
The replicate studies are used to assess significance of the
numbers of categories reaching various P-values and the
study-wide significance levels for individual categories.
Follow-up of top signals from the discovery stage. For the
replication analysis, a follow-up threshold of significance was
set at PGCo1e 05. A total of 16 independent SNPs reaching
this cut-off were considered (Supplementary Table S1 and
S2). For the SNP selection we evaluated the LD pattern of
markers achieving the follow-up threshold with the LD-select
software (r2o0.85; Carlson et al, 2004). Seven markers were
selected for replication in the overall ADHD sample, eight in
the combined and four in the inattentive clinical subtypes
(Supplementary Table S2). Rs1937444 could not be tested
due to experimental constraints and therefore 15 SNPs from
10 loci were finally assessed (Supplementary Table S2). We
performed a single-marker analysis on the replication
samples from the three IMpACT sites separately and then
combined the individual study results using both mega-
analytic and meta-analytic approaches. We assessed HWE in
each control sample and compared genotype frequencies
using Cochran–Armitage trend tests with the SNPassoc R
package (Gonza´lez et al, 2007). Meta-analyses were con-
ducted using the Meta-R package, under a dominant model of
inheritance (Viechtbauer, 2010). To test heterogeneity among
studies we used the Q-statistic and heterogeneity, which was
considered significant when PQo0.10. When no hetero-
geneity was present, the pooled OR was estimated using a
fixed-effects model. Otherwise, a random-effects model was
applied. Under the more conservative Bonferroni correction
taking into account 15 SNPs and three clinical subtypes, the
threshold for significance was set at Po1.1e 03 (0.05/
15 3).
Imputation and gene-based association analysis. Mar-
kers at the FBXO33 (F-box only protein 33 gene) locus
(ch14:39865674–39902852) were imputed in the discovery
sample with the BEAGLE software using data from the 1000
Genomes Project (http://www.1000genomes.org/; Browning
and Browning, 2009). The association analysis was per-
formed using the Cochran–Armitage trend test with PLINK
(Purcell et al, 2007). The significance threshold under the
Bonferroni correction was set at Po4.7e 04, considering
the 107 SNPs analyzed in the FBXO33 locus. The prediction
of the potential effects of the risk alleles associated with
ADHD were tested using CFSSP (Chou & Fasman Secondary
Structure Prediction Server), SNPinfo, TFSearch, ESEfinder,
ESRSearch, and RESCUE_ESE (Chou and Fasman, 1974;
Cartegni et al, 2003; Fairbrother et al, 2002; Heinemeyer
et al, 1998; Wang et al, 2004; Xu and Taylor, 2009) as well as
the Ensembl database (http://www.ensembl.org/).
Cis Expression Quantitative Trait Loci Analysis
FBXO33 expression levels and genotype data for rs17696574,
rs10139591, rs7156962, and rs1056345 from 210 unrelated
HapMap individuals, including Utah residents with North-
ern and Western European ancestry from the CEPH
collection (CEU, n¼ 60); Han Chinese from Beijing, China
(CHB, n¼ 45); Japanese from Tokyo, Japan (JPT, n¼ 45);
and Yoruban from Ibadan, Nigeria (YRI, n¼ 60), were
obtained from the whole-genome Illumina lymphoblastoid
cell line gene expression data and the HapMap browser
(http://www.hapmap.org) (International HapMap Consor-
tium (2003)), respectively. No genotype data were available
for marker rs12232110. For the expression data we
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considered the GSE6536 series dataset at the Gene Expres-
sion Omnibus site (http://www.ncbi.nlm.nih.gov/geo;
Stranger et al, 2007a; Stranger et al, 2007b) and selected
the GI_42558257-S probe corresponding to the FBXO33
transcript NM_203301.3. Association tests between genetic
markers and FBXO33 expression were performed using
linear regression models with SPSS 17.0 (SPSS, Chicago,
USA) and the significant threshold was set at 0.0125 (0.05/4
SNPs) after applying the Bonferroni correction.
Brain Imaging Studies
To further understand the effects of ADHD-related SNPs
in FBXO33, we tested rs17696574, rs12232110, rs10139591,
rs7156962, and rs1056345 for their effects on brain structure
in a pre-existing neuroimaging genetics sample, consisting
of 1300 adult subjects (age range 18–40 years, average age
22.9 years) from the Dutch Cognomics Resource Brain
Imaging Genetics (BIG; www.cognomics.nl). All participants
were self-reportedly healthy subjects of Caucasian descent
with no ADHD diagnosis. Genetic data were available from
an Affymetrix Genome-Wide Human SNP Array 6.0 and
imputed using the 1000 Genomes reference set. The effects
of the genetic variation on structural brain changes were
tested using voxel-based morphometry (VBM). For this,
structural T1 brain scans acquired at 1.5 and 3 Tesla scanners
(Siemens, Erlangen, Germany) were used (Supplementary
Material). To study the effects of the specific SNPs, a
full-factorial ANCOVA was performed using genotype as
factor and age, gender, total brain volume, and field
strength of the scanner as covariates. Gray and white
matter images were analyzed separately. Statistics
were corrected for non-stationarity and were applied at
Puncorrectedo1e 04. Significant clusters were considered at
a level of PFWEo0.05. We specified our regions of interest
using the WFU pickatlas (Maldjian et al, 2003). These
regions included the frontal lobe, caudate nucleus, and the
cerebellum selected based on information on FBXO33 gene
expression in combination with knowledge of brain regions
implicated in ADHD (Cubillo and Rubia, 2010).
RESULTS
Genome-Wide Association Study
In the first stage of the study and after individual and SNP-
based standard quality control filtering, we conducted a
GWAS in a discovery sample of 603 adult ADHD cases and
583 healthy controls. The quantile–quantile plot showed no
departure from the expected P-values distribution with a
genomic control inflation factor l¼ 1.031 used as a final
quality control measure (Supplementary Figure S1). None of
the association signals exceeded genome-wide thresholds
for significance (PGCo1.7e 08). The GWAS of the overall
sample, however, highlighted 12 SNPs from five loci that
surpassed the follow-up threshold (PGCo1e 05), five of
which were located in four genes, PEX19 (rs10594, PGC¼
3.69e 06), COPA (rs7522166, PGC¼ 1.97e 06 and
rs6669995, PGC¼ 6.43e 06), FBXO33 (rs12590172, PGC¼
7.40e 06), and KCNG4 (rs11646443, PGC¼ 6.51e 07;
Table 1; Supplementary Figure S2). When patients were
subdivided according to clinical subtype, we identified eight T
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loci in which one or more SNPs showed evidence for
association with combined or inattentive ADHD subtypes
after considering the cut-off of PGCo1e 05, with the top
signal at rs2232429 (PGC¼ 8.88e 08; Tables 2 and 3;
Supplementary Figure S2). Six of them were located in five
genes: ZSCAN12 (rs2232429, PGC¼ 8.88e 08), FBXO33
(rs3814860, PGC¼ 8.72e 06 and rs12590172, PGC¼ 3.96
e 06), KCNG4 (rs11646443, PGC¼ 8.39e 07), PDE4B
(rs1937444, PGC¼ 7.12e 06), and ACCN1 (rs1988353,
PGC¼ 1.16e 06; Tables 2 and 3; Supplementary Figure
S2). The proportion of variance for ADHD explained by the
794 090 autosomal SNPs was estimated at 0.25 (SE¼ 0.01;
P¼ 1.2e 08), 0.24 (SE¼ 0.011; P¼ 6.6e 06), and 0.19
(SE¼ 0.07; P¼ 2.9e 05) for overall, combined, and in-
attentive ADHD, respectively.
Follow-up of Top Signals from the Discovery Stage
Fifteen SNPs from 10 loci with a significance level of
PGCo1e 05 in the discovery sample were taken forward
for follow-up in three independent clinic-based adult ADHD
samples (2104 cases and 1901 controls). Although nominal
associations were detected in some of the populations under
study (Supplementary Table S3–S4), no significant differ-
ences were observed in the joint analysis of the three
replication cohorts neither through a mega-analysis
(Supplementary Table S3–S4) nor in a meta-analysis (data
not shown).
We subsequently considered the available data from both
the discovery and replication stages and, although none
of the markers surpassed genome-wide significance, some
remained nominally associated with ADHD. When the
overall ADHD sample was considered in the pooled ana-
lysis, six out of seven SNPs were nominally associated with
ADHD: rs10594 (P¼ 8.4e 04), rs11644983 (P¼ 6.6e 04),
rs2415545 (P¼ 9.7e 03), rs4902569 (P¼ 0.014),
rs11646443 (P¼ 0.049), and rs1897792 (P¼ 0 05; Supple-
mentary Table S3). Rs10594 and rs11644983 showed a
significant association with ADHD in the German or
Norwegian samples, respectively, with consistent effect size
for the same risk allele identified in the discovery sample.
When patients were subdivided according to the ADHD
subtypes, the five SNPs tested at the FBXO33 locus
remained associated with combined ADHD, rs4902569
(P¼ 5.9e 03), rs2415543 (P¼ 6.4e 03), rs2415545
(P¼ 3.0e 03), rs3814860 (P¼ 2.5e 03), and rs17696574
(P¼ 3.1e 03; Supplementary Table S4a). Positive signals
were also observed for the three SNPs considered in the
inattentive ADHD sample, rs12333188 (P¼ 3.0e 04),
rs1962749 (P¼ 2.1e 04), and rs1988353 (P¼ 2.3e 04;
Supplementary Table S4b). The mega-analysis, however,
showed less significant results for all SNPs than the analysis
of the discovery sample.
We subsequently performed a meta-analysis considering
the discovery and replication sample sets and, after having
detected heterogeneity among populations, a single positive
signal was identified at rs17696574, located 50 from FBXO33,
in the combined ADHD clinical subtype (ORrandom¼ 1.34
(1.01–1.78); P¼ 0.041; Table 4 and Supplementary Tables
S5–S7). Although the same analysis in the replication
cohorts alone showed borderline significant association
(combined ADHD: ORrandom¼ 1.20 (0.99–1.46), P¼ 0.056; T
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Table 4b), directionally consistent effects were observed in
the populations under study and these differences remained
significant when we considered the overall ADHD cohort
(ORfixed¼ 1.24 (1.06–1.44; P¼ 5.7e 03).
To better delineate the involvement of FBXO33 in
combined ADHD and to detect potential functional
variants, we imputed markers at this locus in the discovery
cohort. Although the locus imputation did not identify any
genome-wide significant signal, imputed SNPs within the
locus provided stronger evidence for association than
genotyped SNPs (Figure 1; Supplementary Table S8).
Positive signals were identified along the entire gene, with
the top signal, rs12232110 (P¼ 9.02e 07), located in intron
1 (Supplementary Table S8). Although conditioning for the
effect of rs12232110 eliminated evidence for association
for the majority of SNPs in close proximity, this marker did
not explain the entire signal at FBXO33 since a second
independent SNP, rs10139591, maintained significance with
combined ADHD (P¼ 4.7e 04). This second marker is
also located in intron 1, lies 1.5 kb from rs12232110 and
resides in a haplotype block that encompasses the entire
FBXO33 gene (Figure 1). Other candidate SNPs within the
region were also nominally associated with combined
ADHD when conditioning for the effect of rs12232110 and
include rs7156962 (P¼ 0.05) and rs1056345 (P¼ 3.1e 03)
in exons 3 and 4 of the FBXO33 gene, respectively. Given
that multiple SNPs mapped to FBX033, we performed a
gene-wise association test based on all the SNPs in the gene
(n¼ 17) and found additional evidence for its involvement
in ADHD (gene-based P-value¼ 1e 06 for overall and
combined ADHD). Since FBXO33 acts as a substrate-
recognition component of a protein–ubiquitin ligase com-
plex, we also examined the joint effect of genetic variation
in biological pathways. After quality control procedures,
genotypes on 750 222 SNPs were considered, of which
443 335 lay within genes, covering 22 947 genes and 6188
categories. The pathway analysis showed a total of 293 out
of 5264 GO categories reaching nominal significance for
over-representation in our GWAS dataset. Among them,
significant results were observed for the gene set/pathway
referenced as ‘protein ubiquitination’ (GO:0016567), which
includes the FBXO33 gene (P¼ 0.016; 41 significant genes
out of 81 genes in this GO category), and for 31 additional
GO categories related to neuronal development, differentia-
tion, and activity (Supplementary Table S9). When the
FBXO33 gene was excluded from the pathway analysis, the
‘protein ubiquination’ category remained significantly over-
represented in our GWAS dataset (P¼ 0.026).
To provide insight into the molecular mechanisms behind
the top FBXO33 SNPs associated with ADHD, we searched
for cis eQTLs (expression quantitative trait loci) using a
pre-existing dataset (GSE6536; Stranger et al, 2007a;
Stranger et al, 2007b) and performed neuroimaging genetics
studies using VBM analyses. In total, five SNPs within
the FBXO33 locus were considered: rs17696574, identified in
the joint meta-analysis of the discovery and the replication
samples, rs12232110 and rs10139591, the two independent
top signals identified in the discovery sample after genotype
imputation, and rs7156962 and rs1056345, two intragenic
SNPs nominally associated with ADHD that were located in
exons 3 and 4 of the FBXO33 gene, respectively. FBXO33
expression levels in HapMap lymphoblastoid cell lines wereT
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significantly associated with genotypes in a dose-dependent
manner for rs17696574 and rs7156962 (eQTL P¼ 0.024 and
P¼ 8.7e 03, respectively), with lower FBXO33 expression
being associated with the rs17696574G and rs7156962C risk
alleles (Supplementary Figure S3). After applying the
Bonferroni correction, only rs7156962 remained associated
with FBXO33 expression levels.
When we investigated the role of FBXO33 SNPs in the
brain considering the frontal lobe, caudate nucleus and the
cerebellum as regions of interest, we found a nominally
significant effect of rs1056345 (AA (n¼ 406)/TA (n¼ 603)/
TT (n¼ 211)) on frontal gray matter (peak voxel
x¼  56, y¼  8 and z¼ 49; cluster PFWE¼ 0.02), with
FBXO33 risk genotypes being nominally associated with
reduced gray matter volume (Supplementary Figure S4).
This effect was observed on the border of the frontal lobe
and the parietal lobe, covering parts of the left post-central
gyrus, an area that is involved in motor processing, which is
a deficient cognitive domain in ADHD (Stray et al, 2013).
No significant effects were found for the other SNPs or
brain regions.
DISCUSSION
We have completed a genome-wide association scan and
a follow-up replication study on adult ADHD. To our
knowledge, this is the first GWAS on the persistent form of
the disorder following individual genotyping, since the only
one reported so far used DNA pooling (Lesch et al, 2008).
Our results show that common SNPs in total explain 0.25
(SE¼ 0.01) of phenotypic variance for adulthood ADHD,
similar to the 0.28 (SE¼ 0.02) described in a previous study
of childhood ADHD (Lee et al, 2013). Although none of the
findings exceeded genome-wide thresholds for association,
neither in the discovery cohort nor in the follow-up meta-
analysis, the results of the present study show tentative
evidence for the involvement of the FBXO33 gene in the
susceptibility to adult ADHD.
FBXO33 is a member of the F-box protein family that
acts as a substrate-recognition component of a protein–
ubiquitin ligase complex involved in targeting substrates for
proteasomal degradation. FBXO33 has embryonic and
adulthood expression in a wide range of neural tissues
and has previously been associated with autism spectrum
disorders in two large cohorts and with the neural response
to seizure (Flood et al, 2004; Tai and Schuman, 2008; Wang
et al, 2009). In addition, a deletion of chromosome 14 that
spans the FBXO33 gene was identified in a patient with signs
of attention deficit, hyperactivity, and mild mental retarda-
tion (de Bruijn et al, 2010). Furthermore, a balanced
t(14;21)(q21.1;p11.2) translocation involving the FBXO33
gene was also reported in a patient with severe progressive
autism (de Bruijn et al, 2010). These results are in
agreement with previous studies pointing to a shared
genetic etiology between ADHD and autism and support the
view that common risk factors may be involved in both
disorders as well as in their comorbidity (Nijmeijer et al,
2010; Rommelse et al, 2010).
To our knowledge, this is the first study suggesting a role
of the ubiquitination machinery in ADHD, which is in line
with previous reports showing association between genes
from the ubiquitin family and autism, bipolar disorder, or
intellectual disability (Glessner et al, 2009; Ryan et al,
2006; Tai and Schuman, 2008). Although the ubiquitin–
proteasome pathway modulates synaptic activity, neuro-
transmitter release, and synaptic vesicle recycling, the
exact mechanism by which FBXO33 contributes to ADHD
remains to be elucidated. Our expression study suggests that
decreased FBXO33 levels may underline the vulnerability to
Table 4 Effect of rs17696574 on combined ADHD considering (a) the discovery and replication cohorts or (b) the replication cohorts
alone
Fixed effect model
Random effects model
Heterogeneity: I-squared = 59.3%, tau-squared = 0.0485, P = 0.0611
328
748
192
289
1807
 360
 873
 227
 347
486
603
520
428
2469
 582
 718
 613
 556
0.5 1 2
1.32
1.34
2.02
1.14
0.98
1.49
 1.11; 1.58
 1.01; 1.78
 1.33; 3.09
 0.87; 1.50
 0.64; 1.50
 1.06; 2.10
100
–
14.6
41.9
19.2
24.3
–
100
21.7
30.4
21.8
26.1
Fixed effect model
Random effects model
Heterogeneity: I-squared = 20.7%, tau-squared = 0.008, P = 0.2834
748
192
289
1447
 873
 227
 347
603
520
428
1887
 718
 613
 556
0.5 1 2
1.20
1.20
1.14
0.98
1.49
 0.99; 1.46
0.97; 1.49
 0.87; 1.50
 0.64; 1.50
 1.06; 2.10
100
–
49.1
22.4
28.5
–
100
45.0
22.9
32.1
Discovery
Germany
Netherlands
Norway
ADHD Controls
Study GG+GA Total GG+GA Total OR OR 95% (CI) WeithFixed (%) WeithRandom(%) Z P-value
3.18 0.0015
2.04 0.041
Germany
Netherlands
Norway 
1.91 0.056
1.64 0.10
Data in bold correspond to the summary statistics of the meta-analysis.
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ADHD, which is in agreement with the downregulation of
ubiquitin cycle-related genes identified in bipolar post-
mortem brains (Ryan et al, 2006). Reduced expression of
enzymes involved in this pathway may thus impair targeting
of proteins for proteasomal degradation and hence the
turnover of synaptic components. The association between
the FBXO33 risk variant at the 30UTR of the gene and
reduced gray matter volume in the left post-central gyrus, a
region that is part of the attention network of the brain and
shows altered activity in patients with combined subtype
ADHD (Silk et al, 2005), also supports the role of FBXO33 in
the pathogenesis of ADHD. Further studies are needed to
confirm whether FBXO33 expression is involved in ADHD
and to determine the potential mechanism by which
reduced expression of this gene may contribute to the
susceptibility to the disorder.
Although the top SNP from this association study,
rs17696574, is located 65.8 kb upstream from FBXO33, its
involvement in ADHD is supported by multiple highly
correlated SNPs within the gene region as well as by the
gene-wise association analysis (Figure 1). Interestingly,
rs7156962, an evolutionary conserved synonymous change
in exon 3 of FBXO33, may affect the regulation of splicing,
with the rs7156962C risk allele altering putative exonic
splicing enhancers. This sequence variant has a functional
significance score (FS) of 0.77, which may reflect its
potential deleterious effect (Lee and Shatkay, 2009). Other
SNPs within the FBXO33 locus highlighted in the present
study may also deserve further attention, since they are
highly conserved (rs3814860), affect highly methylated
regions (rs12232110), or alter transcription factor binding
sites (TFBS; rs2415543). In addition, all these sequence
variants, with the exception of rs2415543, are associated
with trimethylated histone H3 at lysine 36 (H3K36me3),
which is related with transcriptionally active regions.
Finally, the correlation between genotypes at rs17696574
or rs7156962, a synonymous change in exon 3, and FBXO33
expression levels in lymphoblastoid cell lines also suggests
functional relevance and reinforces the possibility of true
causality. In any case, the analysis of gene expression in
brain tissue is required to confirm this correlation.
Given that the two top-ranked SNPs associated with
ADHD after locus imputation, rs12232110 and rs10139591,
are located in intron 1 of FBXO33 and contained in a LD
block that spans the entire gene (Figure 1), we cannot rule
out that additional coding variants in FBXO33 might exert
functional effects. It also remains an open issue whether
disease vulnerability is driven by a single variant or by
multiple independent SNPs within the region. Further fine
mapping and deep sequencing of this genomic region is
required to identify causal sequence variants directly
involved in the genetic background of ADHD.
Although we have attempted to minimize limitations of
previous GWAS, the outcome of the present study should be
interpreted in the context of several considerations.
First, to minimize population stratification and genetic
heterogeneity we focused on the persistent form of ADHD.
Despite the fact that genetic studies have mainly focused on
children, there is evidence pointing to the existence of an
even stronger genetic component in adult ADHD
(Biederman, 2005; Biederman and Faraone, 2005; Chang
et al, 2013; Faraone et al, 2005). In addition, different lines
of investigation suggest a distinct genetic load between
persistent and remitting ADHD, and support the existence of
specific genetic factors contributing to the stability of ADHD
symptoms across life (Kuntsi et al, 2005; Price et al, 2005;
Ribases et al, 2008). Thus, previous GWAS focused on
childhood ADHD may have increased heterogeneity by
including in the analysis the subset of patients in whom
ADHD will remit.
Second, nominal signals were detected both in the
discovery cohort and in the joint analysis of the discovery
and replication samples, but only borderline significance
was observed when the replication cohorts were considered
alone. Although this is not a standard replication-based
design, the analysis combining the information from both
the discovery and replication samples may be more powerful
than treating the design as a hypothesis generation followed
by independent replication (Skol et al, 2006). Further studies
in additional samples and a truly independent replication
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Figure 1 Regional association plot including the FBXO33 locus on
chromosome 14q13.3 from data imputed using the 1000 Genomes Project
dataset. The x-axis shows physical distance (kb) and y-axis shows  log (P)
values when considering the combined ADHD discovery cohort. In the
upper panel genotyped and imputed markers are indicated in black and red
dots, respectively. In the lower panel, the color reflects the degree of
linkage disequilibrium (r2) between each genotyped (circled) or imputed
(squared) marker with the most associated genotyped SNP, rs17696574,
shown in diamond.
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are warranted both to confirm the association between
FBXO33 and ADHD and to estimate the magnitude of its
effect.
Third, a part from variation in FBX033, we failed to
replicate in our validation cohort any of the top-ranked
associations that achieved the follow-up threshold of
significance in the discovery stage. Although these results
provide little support for association with genes other than
FBXO33, several top findings deserve further comments.
PEX19 and COPA encode the peroxisomal farnesylated
protein and the subunit alpha of the coatomer protein
complex, respectively, and they have been associated with
different psychiatric disorders. PEX19 was associated with
major depression in a meta-analysis carried out by the
Psychiatric GWAS Consortium (Ripke et al, 2013b), while
COPA expression has been found dysregulated in the
orbitofrontal cortex of bipolar disorder patients (Ryan
et al, 2006). In addition, KCNG4 codes for a regulatory
subunit of voltage-gated potassium channels highly
expressed in the brain, involved in the regulation of neuro-
transmitter release and neuronal excitability, and associated
with migraine (Lafreniere and Rouleau, 2012). Interestingly,
although rs11646443, the missense change (c.616G4A,
p.Arg206Trp) in KCNG4 found associated with ADHD in
the present study may not change the secondary structure
of the protein or have damaging effects on its function,
it might affect the regulation of splicing, since the
rs11646443G risk allele lies within a putative exonic splicing
repressor. Finally, PCDH17 belongs to the protocadeherin
family and its product participates in synaptic function and
cell–cell adhesion activity, which has been previously
associated with ADHD (Lesch et al, 2008; Neale et al,
2008; Neale et al, 2010b; Rivero et al, 2013; Zhou et al,
2008). These promising candidates may be considered as
potential ADHD-related loci worth replicating in larger
sample sets.
In addition, the results from our GWAS do not identify
hits from previous GWAS or provide genome-wide signi-
ficant support for any of the previously postulated
candidate genes for ADHD (Franke et al, 2009; Hinney
et al, 2011; Lesch et al, 2008; Mick et al, 2010; Neale et al,
2008; Stergiakouli et al, 2012). No overlap or LD was
observed between our main hits and the top-ranked
findings from previous GWAS reports either. Confounding
factors, such as comorbidities, IQ, or environmental
influences that may modulate the genetic mechanisms
predisposing to ADHD could help to explain that positive
signals in previous studies do not reach genome-wide
significance in our study or were not ranked high enough to
be included in our replication stage. It is worth pointing
out, however, that rs1937444 in the PDE4B gene showed a
borderline significant association with adulthood ADHD in
a previous GWAS performed in the persistent form of the
disorder (Supplementary Table S10; Lesch et al, 2008).
Interestingly, this gene was previously associated with
schizophrenia (Millar et al, 2005) and an identically active
isoform, the brain-specific phosphodiesterase 4D isoform 6
(PDE4D6), was found duplicated in an ADHD family (Lesch
et al, 2011).
Fourth, we aimed to improve our GWAS design by
focusing not only on SNPs contributing to the overall risk
for ADHD, but also on markers that may participate in the
combined or inattentive clinical subtypes. Following this
strategy, which allows capturing additional associations that
might have been skipped in previous studies that focused
on the overall ADHD sample, we found preliminary
evidence for the involvement of FBXO33 in combined
ADHD but not in the inattentive subgroup. These findings
are in agreement with previous reports pointing to the
validity of the DSM-IV distinction between the combined
and predominantly inattentive types, support previous
studies that find differential genetic components across
ADHD subtypes and suggest that the combined group may
represent a distinctive and more homogeneous phenotype
that may facilitate the identification of genetic factors
contributing to ADHD (Larsson et al, 2006; Ribases et al,
2008; Ribases et al, 2009; Todd et al, 2001). Thus, the
identification of phenotypic characteristics that define
subgroups of patients affected by specific sets of genes,
such as clinical subtypes, may be an alternative approach to
reduce genetic heterogeneity in ADHD. However, we cannot
exclude that the limited sample size of the inattentive group
may account for the absence of association observed when
this ADHD subtype was considered.
Fifth, since heterogeneity may increase in large multi-site
designs, cases and controls included in the discovery sample
were recruited by a single clinical group in a restricted
geographic area (Barcelona) and had the same ethnic
background (Spanish Caucasian). Diagnosis of ADHD was
based on structured, systematic interviews with no varia-
bility in measurements across data. We used one single
ascertainment approach with homogeneous semi-structured
diagnostic assessments, which may facilitate the identifica-
tion of risk variants that might be neglected by a broader
recruitment strategy used in previous multi-site GWAS. In
addition, given that using controls unscreened for the
presence of the disorder and genotyping with different
platforms may reduce power, the presence of ADHD-related
symptoms was excluded in our controls, and a single
genotyping platform, Illumina HumanOmni1-Quad, was
used for both affected individuals and controls. However,
despite our efforts to increase the homogeneity of the
discovery cohort, our discovery GWAS did not have
sufficient statistical power to unequivocally detect small to
medium effects of common SNPs on ADHD at a genome-
wide significant level. Our negative results may be explained
by the existence of small genetic effects also in the adult
form of ADHD, which would require larger and homo-
geneous sample collections and further replication efforts to
be reliably identified.
In conclusion, we performed a two-step GWAS to identify
genetic risk factors for persistent ADHD. Our findings show
tentative evidence for the involvement of FBXO33 in the
susceptibility to adult ADHD, point at the ubiquitination
machinery as a new disease mechanism for the disorder and
establish a rationale for searching additional risk variants
within ubiquitin-related genes through additional colla-
borative efforts.
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